Meanwhile, Switzerland’s relative regulatory independence, via its own health authority Swissmedic, could provide some ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

The company’s Q3 results and announced deal with Novartis (NVS) involving both a research and expanded software utilization collaboration drove the stock higher, and while operating results from the ...

Purpose-led collaboration is not just a buzzword; it is a strategic approach where all stakeholders come together with a ...

The majority of U.S. stock indices ended lower on Nov. 12, as rising U.S. treasury yields posed a headwind to the equities’ ...

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...

Gabriele Ricci, chief data and technology officer, has been reorganizing the technology function at Takeda Pharmaceutical.

Sandoz Inc., Pfizer Inc., and Amneal Pharmaceuticals Inc. are among a group of generic-drug manufacturers that will face some ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

Novartis (NVS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall ...